Journal of Vascular and Interventional Radiology

11/19/2025

**NEW IN JVIR:** First-in-Human Evaluation of a New Resorbable Microspherical Embolic Agent for Genicular Artery Embolization to Treat Pain Secondary to Knee Osteroarthritis

🔍 **Clinical Question:**
Is genicular artery embolization (G*E) using a resorbable microspherical embolic agent a safe and effective treatment for pain secondary to knee osteoarthritis (KOA)?

💡 **Key Insight:**
This first-in-human study reports on the feasibility, safety, and effectiveness of a new resorbable embolic agent, SakuraBead (CrannMed, Galway, Ireland), specifically designed for musculoskeletal embolotherapy.

Fifteen patients underwent successful genicular artery embolization with 100% technical success.

There was a statistically significant reduction (P < .001) in mean visual analog scale score of 73.8%, 75.7%, and 63.1% at 1, 3, and 6 months, respectively. There was a 79.1% reduction in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score at both 1 and 3 months, and 75.8% reduction was maintained at 6 months (P < .01); this was accompanied by a reduction in WOMAC pain score of 80.3%, 82.4%, and 78.7% at 1, 3, and 6 months, respectively (P < .01).

👉 **Why it matters:**
This limited pilot study demonstrated that genicular artery embolization using alginate resorbable microspheres was safe and provided significant improvement in pain and function in patients with knee osteoarthritis maintained to 6-month follow-up.

➡️ **Full Article:** https://brnw.ch/21wXDuI

*E

11/13/2025

**NEW IN JVIR:** Mesenteric Lymphangiography as a New Diagnostic and Therapeutic Tool for Refractory Chylous Lymphatic Leakages and Protein-Losing Enteropathy

🔍 **Clinical Question:**
Is mesenteric lymphangiography (mLAG) is technically feasible and clinically useful for patients with refractory chylous ascites, chylothorax, and protein-losing enteropathy (PLE)?

💡 **Key Insight:**
Mesenteric lymphangiography (mLAG), via a percutaneous or intraoperative approach, is technically feasible and safe.

The utility of mLAG is in imaging the blind spots of conventional lymphatic studies, especially for chylous ascites and protein-losing enteropathy, and it allows for embolization of mesenteric lymphatics.

👉 **Why it matters:**
mLAG is technically feasible and safe. It can be a useful tool to image the mesenteric lymphatics or perform mesenteric lymphatic embolization.

➡️ **Full Article:** https://brnw.ch/21wXsEw

11/03/2025

Your November issue of the Journal of Vascular and Interventional Radiology is here! This issue features the MOSAIC Study, a clinical study on a new G*E using a resorbable microspherical embolic agent and an analysis on JVIR and CVIR publications. Read the full issue now: https://brnw.ch/21wXa4Z

10/31/2025

Meet the incoming Journal of Vascular and Interventional Radiology co-editors-in-chief! Charles E. Ray Jr., MD, PhD, FSIR, and Brian F. Funaki, MD, FSIR, are ready to take on the flagship SIR publication in the new year! jvir.org

10/30/2025

**NEW IN JVIR:** Thermal Ablation Modalities That Best Compete with Partial Nephrectomy for T1A and T1B Renal Cell Carcinoma: A Network Meta-Analysis

🔍 **Clinical Question:**
Which thermal ablation modality is best suited for treating T1A and T1B renal cell carcinoma (RCC), in terms of efficacy and safety, from a network meta-analysis?

💡 **Key Insight:**
Percutaneous thermal ablation techniques offer oncologic and safety outcomes comparable with those of surgical interventions for both T1A and T1B renal tumors.
Percutaneous microwave ablation may be highly effective for treating T1A tumors, demonstrating superior outcomes compared with those of partial nephrectomy.
Open partial nephrectomy remains the most effective treatment for T1B tumors.

👉 **Why it matters:**
For patients with T1A tumors, percutaneous microwave ablation demonstrated superior outcomes compared with those of partial nephrectomy. For patients with T1B tumors who are unfit for surgery, percutaneous thermal ablations may serve as viable alternatives.

➡️ **Full Article:** https://brnw.ch/21wX45t

10/21/2025

**NEW IN JVIR:** Radiofrequency Ablation in the Management of Extensive Multinodular Goiter: A Midterm Single-Center Experience

🔍 **Clinical Question:**
Is radiofrequency (RF) ablation effective in providing cosmetic and symptom relief for patients with extensive multinodular goiter?

💡 **Key Insight:**
This study evaluated the effectiveness of radiofrequency (RF) ablation in patients with extensive multinodular goiter, targeting at least 3 nodules in bilobar distribution with a follow-up of 40.5 months.
RF ablation demonstrated a mean volume reduction of 85.3% in treated thyroid nodules, significantly improving both cosmetic appearance and local symptoms.
Repeated RF ablation sessions were required in 32.5% of patients due to additional target nodules, incomplete ablation, or new nodule growth.

👉 **Why it matters:**
Radiofrequency (RF) ablation in patients with extensive multinodular goiter avoids the need for thyroid hormone replacement therapy or surgery and provides a rate of cosmetic and symptom relief comparable with that achieved by RF ablation in cases of uninodular or binodular goiter.

➡️ **Full Article:** https://brnw.ch/21wWOhc

10/17/2025

Your open access Journal of Vascular and Interventional Radiology evidence-based CME article this month is Effectiveness of Transjugular Intrahepatic Portosystemic Shunt Creation for the Treatment of Hepatopulmonary Syndrome. Be sure to read it and claim your CME now: https://brnw.ch/21wWIsl

10/16/2025

Need to understand the requirements to develop a percutaneous arteriovenous fistulas for dialysis access (pAVF) program? See the society-based consensus recommendations in our new practice guidance document by the Renal and Genitourinary Clinical Specialty Council in the Journal of Vascular and Interventional Radiology:

The Society of Interventional Radiology’s (SIR) Renal and Genitourinary Clinical Specialty Council formed a workgroup in collaboration with the SIR Guidelines and Statements Division to create up-to-date society-based consensus recommendations for the creation and maturation of percutaneous arteri...

10/15/2025

**NEW IN JVIR:** Genicular Artery Embolization Using Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Prospective Study

🔍 **Clinical Question:**
Is genicular artery embolization (G*E) using mesenchymal stem cells safe and feasible in patients with bilateral knee osteoarthritis (OA)?

💡 **Key Insight:**
Mesenchymal stem cells were safely delivered via genicular arteries (G*E) to subjects with Kellgren-Lawrence Stage 3 knee osteoarthritis (OA). During a 12-month follow-up period, there were no study-related adverse events.

There were significant improvements in objective pain, stiffness, and function compared with the contralateral control knee.

👉 **Why it matters:**
Direct delivery of stem cells via genicular artery embolization (G*E) by interventional radiology (IR) may represent a new avenue for treatment in patients with osteoarthritis (OA).

➡️ **Full Article:** https://brnw.ch/21wWE0C

*E

10/10/2025

Exciting news! will be online-only starting January 2026. This will allow us to reinvest savings in editorial excellence, peer review infrastructure and enhanced digital features for authors and readers alike. Get alerts 🔔 to stay up to date.

10/09/2025

A 28-year-old man with autism, seizure disorder and cryptogenic cirrhosis underwent revision of his occluded transjugular intrahepatic portosystemic shunt (TIPS) 9 years following the initial placement. Two weeks later, he presented with fever, bilateral pulmonary emboli, and polymicrobial bloodstream infection. Follow the full story through Images in in the latest edition of the Journal of Vascular and Interventional Radiology. Access to this and other articles is free with your SIR membership:

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

10/09/2025

A 28-year-old man with autism, seizure disorder and cryptogenic cirrhosis underwent revision of his occluded transjugular intrahepatic portosystemic shunt (TIPS) 9 years following the initial placement. Two weeks later, he presented with fever, bilateral pulmonary emboli, and polymicrobial bloodstream infection. Follow the full story through Images in in the latest edition of . Access to this and other articles is free with your SIR membership at the link in our bio.